As collaboration between gastroenterologists and the pharmaceutical and medical device industries continues to grow, advisory boards, consulting, educational programs, and research partnerships have become increasingly common. These engagements enable clinicians to share real-world insights that help shape the development, evaluation, and adoption of new therapies and technologies, while also providing access to emerging science, professional networks, and opportunities to influence patient care. The review emphasizes that industry collaboration can be valuable when conducted transparently and ethically. It provides practical guidance on evaluating advisory opportunities, understanding compensation and regulatory requirements, and managing potential conflicts of interest. Ultimately, the goal is to…
Author: Abhay Panchal
Initiating a new program or service line involves an array of challenges, whether in an academic institution, a private setting, or a federally run hospital. At the Scrubs & Heels Leadership Summit 2026, three gastroenterologists who have successfully navigated these obstacles led a discussion with advice for anyone hoping to bring a new program to their institution. Rashmi Advani, MD, an interventional and bariatric endoscopist at Cedars-Sinai, in Los Angeles; Tauseef Ali, MD, the medical executive director of SSM Health Digestive Care, in Oklahoma City; and Daniela Guerrero Vinsard, MD, an advanced endoscopist at the Veterans Affairs medical center in…
Researchers at the University of Twente have developed SeroTab, an electronics-free, swallowable soft robotic capsule that could offer a less invasive alternative to traditional upper gastrointestinal endoscopy for certain diagnostic applications. Guided externally by a handheld magnet, the capsule glides through the stomach, measures gastric acidity in real time using ultrasound-visible hydrogel technology, and can collect stomach fluid samples on demand for laboratory analysis—all without requiring a camera, battery, or wired endoscope.
A Medscape commentary highlights a growing trend in which some patients are more hesitant about evidence-based procedures like colonoscopy while showing greater interest in unregulated peptide therapies, describing this as an “inversion of risk.” Using the example of a 50-year-old postmenopausal patient with iron deficiency anemia who was reluctant to undergo a colonoscopy but interested in peptide treatments, the article illustrates how patients may perceive established medical procedures as riskier than experimental compounds that lack robust clinical evidence. The commentary contrasts the well-established safety, regulation, and clinical evidence supporting colonoscopy with the uncertainty surrounding many peptide therapies marketed for anti-aging,…
The microbiome is increasingly becoming the newest frontier in life sciences with scientists mining for potential discoveries. Microbiome therapy includes probiotics, Fecal Microbiota Transplant (FMT), prebiotics, or engineered microbes to cure diseases, such as C. difficile infection, inflammatory bowel disease and metabolic disorders. The increase in research initiatives and rising number of gut infections along with enhanced microbiome sequencing capabilities is resulting in the positive growth of the microbiome therapeutics industry. The main aim of microbiome therapeutic products is to restore and maintain the normal balance and healthy function of organisms or microbiota in the gut. Researchers, investors and business…
ŌURA and LillyDirect, Eli Lilly’s digital health platform, have announced a collaboration to support people using GLP-1 weight-loss and diabetes therapies by combining access to wearable technology with behavioral health tools. Under the partnership, LillyDirect customers will receive a complimentary Oura Ring sizing kit, making it easier to purchase the wearable. The companies emphasized that the collaboration does not involve sharing patient data, but instead aims to create a broader ecosystem of care that complements prescribed GLP-1 medications. The partnership builds on Oura’s recently launched GLP-1 Insights feature, which integrates continuous biometric tracking with therapy-specific insights. Using data from the…
Labcorp has announced the nationwide availability of ColoSense, the first FDA-approved RNA-based at-home colorectal cancer (CRC) screening test, through its partnership with Geneoscopy. The launch expands Labcorp’s colorectal cancer screening portfolio and follows CMS’s decision to provide Medicare coverage for eligible beneficiaries. The test is also supported by additional commercial coverage and aligns with recommendations from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN). ColoSense is designed to improve screening participation by addressing one of the biggest barriers to stool-based testing: sample collection. Unlike traditional stool tests that require handling or mixing the sample, ColoSense uses a…
Chesterfield, Mo.-based Mercy has opened the Kathryn Ann Meinders Digestive Health Institute on the campus of Mercy Hospital Oklahoma City, establishing what the system describes as the only comprehensive digestive health center within a 500-mile radius of Oklahoma City. According to a June 22 news release, the 52,000-square-foot, two-level facility includes seven procedure rooms, 21 prep and recovery rooms, an inflammatory bowel disease clinic, a hepatology clinic, a motility lab, and ambulatory GI care space.
Plain Language SummaryThis study prospectively collected data from patients undergoing colonoscopy with anesthesia at Beijing Tiantan Hospital (November 2024–June 2025) to build a machine learning model that predicts inadequate bowel preparation using only nonpharmacological parameters. Using three feature selection methods and 5 machine learning algorithms, a Firth regression-based model performed best, with AUC values of 0.718 (95% CI: 0.647–0.789) in training and 0.715 (95% CI: 0.611–0.818) in validation. The resulting clinical prediction tool showed good discrimination (AUC, 0.709; 95% CI: 0.605–0.813). Higher body mass index, waist-to-hip ratio, lower gastrointestinal symptom score, diabetes, and smoking/alcohol score increased risk, whereas hematochezia decreased…
Experts at the 2026 Crohn’s & Colitis Congress argued that so-called “treatment-refractory” IBD is often not true drug failure, but rather the result of factors such as bowel fibrosis, structural damage, immunogenicity, poor drug delivery, delayed therapy changes, or psychosocial barriers. They emphasized that persistent symptoms should prompt clinicians to identify the underlying cause rather than simply cycling through additional therapies. The discussion highlighted growing evidence that fibrotic bowel damage can begin early in Crohn’s disease, with the pediatric RISK study identifying fibrosis-associated gene signatures at diagnosis in children who later developed stricturing disease. The findings reinforce the importance of…